Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.
Maria BoesingKristin AbigMichael BrändleMartin BrutscheEmanuel BurriBjörn C FryeStéphanie GiezendannerJan C GruttersPhilippe HaasJustian HeislerFabienne JaunAnne B Leuppi-TaegtmeyerGiorgia Lüthi-CorridoriJoachim Müller-QuernheimReto NüeschWolfgang PohlFrank RassouliJörg D LeuppiPublished in: Trials (2022)
ClinicalTrials.gov, NCT04536350 . Registered 02 September 2020.
Keyphrases
- end stage renal disease
- coronavirus disease
- study protocol
- ejection fraction
- newly diagnosed
- sars cov
- double blind
- placebo controlled
- phase iii
- clinical trial
- prognostic factors
- squamous cell carcinoma
- cystic fibrosis
- randomized controlled trial
- acute respiratory distress syndrome
- patient reported outcomes
- radiation therapy
- intensive care unit
- phase ii study
- combination therapy